VXRT
NASDAQVaxart Inc
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.33+0.00 (+0.00%)
2026-03-312026-07-06
News · 26 weeks83-35%
2026-01-252026-07-19
Mix5890d
- SEC Filings34(59%)
- Other11(19%)
- Insider8(14%)
- Leadership4(7%)
- Earnings1(2%)
Latest news
25 items- INSIDERDirector Breitmeyer James B was granted 8,315 shares, increasing direct ownership by 11% to 87,115 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- INSIDERDirector Heron Elaine J was granted 39,400 shares, increasing direct ownership by 41% to 135,966 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- INSIDERDirector Watson W. Mark was granted 39,400 shares, increasing direct ownership by 29% to 173,525 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- INSIDERDirector Wheadon David E. was granted 39,400 shares, increasing direct ownership by 84% to 86,150 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- SECVaxart Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart Announces Results of Annual Meeting of StockholdersSOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the "Annual Meeting") in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders. Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations: Election of six director nominees to serve until the 2027 Annual Meeting of StockholdersRatification
- SECVaxart Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 VaccineNo vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) today announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. Participants in this safety cohort received Vaxart’s oral pill vaccine (201 participants dosed) or an approved mRNA vaccine (199 participants dosed) targeting the XBB strain of SARS-CoV-2, the virus that causes COVID-19. No vaccine-related serious adve
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECVaxart Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance EnhancementsCompany to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH SAN FRANCISCO, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced a resolution to the proxy contest in connection with the Company’s 2026 Annual Meeting of Stockholders, reflecting a commitment to value creation, strong corporate governance and constructive engagement with stockholders. Vaxart will initiate
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECVaxart Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAYDetails Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth Dissident Nominees Lack Relevant Clinical-Stage Biotech Expertise, Misrepresented Their Qualifications and Offered No Credible Ideas for Value Creation Vaxart Has Made Multiple Settlement Offers to the Dissident Shareholder Group – Daniel Houle Insists on Making This Proxy Contest About Winning a Seat for Himself Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or t
- PRVaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine TrialLatest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of Key Trial Results SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that it has entered into a contract modification that releases additional funding from BARDA, through a contract with Advanced Technology International ("ATI"), to support continuation of the Company’s ongoing Phase 2b COVID-19 oral
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual MeetingUrges Stockholders to Vote "FOR" ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today mailed a letter to shareholders from the Board's two newest independent directors, James Breitmeyer, M.D., Ph.D., and Kevin Finney, urging them to vote "FOR" ALL six of the company's highly qualified director nominees on the WHITE proxy card in connection with its upc
- PRVaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech ForumSOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two upcoming events surrounding the BIO International Convention, taking place June 22-25, 2026, at the San Diego Convention Center in San Diego, CA. 2026 Taiwan Biotech ForumDate: Sunday, June 21, 2026 Location: The Westin San Diego Gaslamp QuarterTime: 1:30pm – 5:30pm PTSean Tucker, Ph.D., Chief Scientific Officer, will participate in a panel discussing innovative therapeutic modalities in precision
- PRVaxart to Participate in BTIG Infectious Disease Day 2026SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in the BTIG Infectious Disease Day 2026 on June 16. BTIG Infectious Disease Day 2026Date: Tuesday, June 16, 2026Format: 1x1 MeetingsLocation: Virtual Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative. About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery
VXRT FAQ
6 questionsWhat does Vaxart Inc do?
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the...Where does VXRT stock trade?
Vaxart Inc (VXRT) is listed on NASDAQ.What sector and industry is VXRT in?
Vaxart Inc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about VXRT?
Vaxart Inc has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $400.00 price target on 2024-08-15. Recent price targets range from $400.00 to $1500.00.What companies are similar to VXRT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare VXRT side-by-side with any of them on Quantisnow.How can I track VXRT on Quantisnow?
Quantisnow aggregates Vaxart Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VXRT to receive live email and push alerts on every new disclosure.